Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


